- Home
- NBIX
as 02-21-2025 4:00pm EST
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 11.6B | IPO Year: | 1996 |
| Target Price: | $168.35 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.29 | EPS Growth: | 33.20 |
| 52 Week Low/High: | $110.95 - $157.98 | Next Earning Date: | 02-06-2025 |
| Revenue: | $2,355,300,000 | Revenue Growth: | 24.81% |
| Revenue Growth (this year): | 16.29% | Revenue Growth (next year): | 16.90% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | Director | Feb 13 '25 | Sell | $116.69 | 5,844 | $681,914.46 | 524,209 | |
| SHERWIN STEPHEN A | NBIX | Director | Feb 13 '25 | Sell | $116.69 | 13,831 | $1,613,922.79 | 10,673 | |
| Lippoldt Darin | NBIX | Chief Legal Officer | Feb 12 '25 | Sell | $116.75 | 2,184 | $254,992.44 | 43,405 | |
| Gano Kyle | NBIX | Chief Executive Officer | Feb 12 '25 | Sell | $116.85 | 2,558 | $298,908.05 | 139,907 | |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Feb 12 '25 | Sell | $116.73 | 2,154 | $251,427.64 | 44,689 | |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 12 '25 | Sell | $116.78 | 1,551 | $181,129.15 | 20,190 | |
| ABERNETHY MATT | NBIX | Chief Financial Officer | Feb 12 '25 | Sell | $116.86 | 2,558 | $298,923.22 | 35,810 | |
| Onyia Jude | NBIX | Chief Scientific Officer | Feb 12 '25 | Sell | $116.79 | 2,879 | $336,238.63 | 18,089 | |
| ROBERTS EIRY | NBIX | Chief Medical Officer | Feb 12 '25 | Sell | $116.23 | 2,218 | $258,263.72 | 35,640 | |
| Lippoldt Darin | NBIX | Chief Legal Officer | Feb 8 '25 | Sell | $118.25 | 911 | $107,727.03 | 43,405 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?
Simply Wall St.
a day ago
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest
MT Newswires
a day ago
Sector Update: Health Care Stocks Mixed Premarket Friday
MT Newswires
a day ago
Neurocrine Biosciences Approves $500 Million Share Repurchase Program
PR Newswire
a day ago
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Argus Research
4 days ago
NBIX: Lowering target price to $120.00
Insider Monkey
4 days ago
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
MT Newswires
4 days ago
Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.